Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Partial Dissection of 10-Q

Partial Dissection of 10-Q

posted on Apr 21, 2009 08:59AM

You can draw your own conclusions from the calculated percentages below. It seems to me that the numbers are not unusual for such a company as PTSC. A few of my observations are below.

· R&D of $117,781 per Q equates to less than 4 good engineer’s salary. All engineering salaries may not be included under the R&D entry, but the number could be a concern given the fast moving competitive market they are in. Does anyone else have a better interpretation of this number?

· We can only guess at which part of costs are fixed and which parts are variable. Variable costs often go up as sales go up.

· Minimum additional revenue required to breakeven (assuming all expenses are fixed – simplistic, they are not) would be $2,529,354. Total revenue would then have been 3,939,555. So we might guess that the most optimistic estimate is PTSC needs at least $4M in gross revenue to breakeven. Looking at expenses %, a more realistic estimate might be at least $8M gross income to breakeven.

· Note: Each $4 million of net income = 1 cent earnings per share. My guess is they need $8M in gross income to breakeven, then an additional $8M gross income for each 1 cent EPS.

Product

License

Total

% of Revenue

Revenue

$1,193,378

$216,823

$1,410,201

Cost of Sales

$534,555

$89,195

$534,555

% of Revenue

44.8%

41.1%

37.9%

Amortization of intangibles

$223,902

% of Revenue

15.9%

Total Cost of Sales

$758,457

% of revenue

53.8%

Operating Expenses

R&D

$117,781

8.4%

Selling & Administration

$2,088,100

148.1%

Total Operating Expenses

$2,205,881

% of Revenue

156.4%

Cost of Sales + Operating Expenses

$2,964,338

% of Revenue

210.2%

Loss before taxes

$2,529,354

Share
New Message
Please login to post a reply